The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.
 
Erica Mayer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis
 
Dario Trapani
No Relationships to Disclose
 
Se Kim
No Relationships to Disclose
 
Meredith Faggen
No Relationships to Disclose
 
Natalie Sinclair
No Relationships to Disclose
 
Pedro Sanz-Altamira
Honoraria - Aptitude Health; Cardinal Health; Curio Science; Kura Oncology; MDoutlook; OMNI Health Media; Zetagen therapeutics
Consulting or Advisory Role - Aptitude Health; Cardinal Health; Curio Science; Kura Oncology; MDoutlook; OMNI Health Media; Zetagen Therapeutics
 
Chiara Battelli
No Relationships to Disclose
 
Shana Berwick
No Relationships to Disclose
 
K.M. Steve Lo
No Relationships to Disclose
 
Jose Acevedo
No Relationships to Disclose
 
Sarah Sinclair
No Relationships to Disclose
 
Alys Malcolm
No Relationships to Disclose
 
Leticia Varella
No Relationships to Disclose
 
Sarah Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Incyclix Bio; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
 
Susan Schumer
Stock and Other Ownership Interests - Johnson and johnson (I)
 
Philip Poorvu
Other Relationship - Medscape
 
Erin Wallace
No Relationships to Disclose
 
Esther Pasternak
No Relationships to Disclose
 
Nabihah Tayob
No Relationships to Disclose
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences